CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?

International Journal of Cardiology

Volumn 120, Issue 1, 2007, Pages 108-114

  Hedman, Anders ^a   Larsson, P Thomas ^a   Alam, Mahbubul ^a   Wallen, N Håkan ^b,c   Nordlander, Rolf ^a   Samad, Bassem Abdel ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

C reactive protein; Coronary artery bypass grafting; Endothelin; Fibrinogen; Interleukin 6; Statins

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; INTERLEUKIN 6;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GRAFT OCCLUSION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; RISK; STABLE ANGINA PECTORIS;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; ENDOTHELIN-1; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34347212790     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.09.004     Document Type: Article

References (51)

1. Caracciolo E.A., Davis K.B., Sopko G., et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 91 (1995) 2335-2344
2. Yusuf S., Zucker D., Peduzzi P., et al. Effect of coronary artery bypass surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 8922 (1994) 563-570
3. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 29 3 (1997) 706-707
4. Domanski M.J., Borkowf C.B., Campeau L., et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts. The postcoronary artery bypass graft trial. J Am Coll Cardiol 36 6 (2000) 1877-1883
5. Motwani J.G., and Topol J.G. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation 97 (1998) 916-931
6. van Brussel B.L., Voors A.A., Ernst J.M., Knaepen P.J., and Plokker H.W. Venous coronary artery bypass surgery: a more than 20-year follow-up study. Eur Heart J 24 10 (2003) 927-936
7. Knatterud G.L., White C., Geller N.L., et al. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J 145 2 (2003) 262-269
8. White C.W., Gobel F.L., Campeau L., et al., Post Coronary Artery Bypass Graft Trial Investigators. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 104 22 (2001) 2660-2665
9. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 9 (2002) 1135-1143
10. Shimizu K., Aikawa M., Takayama K., Libby P., and Mitchell R.N. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108 17 (2003) 2113-2120
11. Morikawa S., Takabe W., Mataki C., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9 4 (2002) 178-183
12. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
13. Kinlay S., Schwartz G.G., Olsson A.G., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 13 (2003) 1560-1566
14. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 20 (2002) 1557-1565
15. Sattar N., Gaw A., Scherbakova O., et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 4 (2003) 414-419
16. Lindahl B., Toss H., Siegbahn A., Venge P., Wallentin L., and FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during instability in coronary artery disease. N Engl J Med 343 16 (2000) 1139-1147
17. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 15 (2000) 1767-1772
18. Myers G.L., Rifai N., Tracy R.P., et al. CDC; AHA.CDC/AHA workshop on markers of inflammation and cardiovascular disease. Circulation 110 (2004) e545-e549
19. Jabs W.J., Theissing E., Nitschke M., et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 108 12 (2003) 1428-1431
20. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 16 (2003) 1930-1932
21. Verma S., Li S.H., Badiwala M.V., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
22. Rahel B.M., Visseren F.L., Suttorp M.J., et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res 60 1 (2003) 136-140
23. Zouridakis E.G., Schwartzman R., Garcia-Moll X., et al. Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J 22 (2001) 1578-1584
24. Kinlay S., Behrendt D., Wainstein M., et al. Role of endothelin-1 in active constriction of human atherosclerotic coronary arteries. Circulation 104 (2001) 1114-1118
25. Ihling C., Szombathy T., Bohrmann B., Brockhaus M., Schaefer H.E., and Loeffler B.M. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104 (2001) 864-869
26. Paz M.A., Lupon J., Bosch X., Pomar J.L., Sanz G., and The GESIC Study Group. Predictors of early saphenous vein aortocoronary bypass graft occlusion. Ann Thorac Surg 56 5 (1993) 1101-1106
27. Libby P., and Simon D.I. Inflammation and thrombosis: the clot thickens. Circulation 103 13 (2001) 1718-1720
28. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., and Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 2 (1993) 513-520
29. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 3 (2003) 398-404
30. Cotton J.M., Hong Y., Hawe E., et al. Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6. Thromb Haemost 89 3 (2003) 538-543
31. Lindmark E., Diderholm E., Wallentin L., and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286 17 (2001) 2107-2113
32. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 8 (2002) 913-919
33. Tomai F., Crea F., Gaspardone A., et al. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion. Circulation 104 (2001) 1471-1476
34. Fichtlscherer S., Rosenberger G., Walter D.H., Breuer S., Dimmeler S., and Zeiher A. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102 (2000) 1000-1006
35. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104 (2001) 992-997
36. Walter D.H., Fichtlscherer S., Britten M.B., et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 38 7 (2001) 2006-2012
37. Milazzo D., Biasucci L.M., Luciani N., et al. Elevated levels of C-reactive protein before coronary artery by pass grafting predict recurrence of ischemic events. Am J Cardiol 84 (1999) 459-461
38. Biancari F., Lahtinen J., Lepojarvi S., et al. Preoperative C-reactive protein and outcome after coronary artery bypass surgery. Ann Thorac Surg 76 6 (2003) 2007-2012
39. Gaudino M., Nasso G., Andreotti F., et al. Preoperative C-reactive protein level and outcome following coronary surgery. Eur J Cardiothorac Surg 22 4 (Oct 2002) 521-526
40. *. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1729
41. Volzke H., Robinson D.M., Kleine V., et al. Preoperative plasma fibrinogen levels predict mortality after coronary artery bypass grafting. Thromb Haemost 89 5 (May 2003) 885-891
42. Kapiotis S., Jilma B., Szalay T., et al. Evidence against an effect of endothelin-1 on blood coagulation, fibrinolysis, and endothelial cell integrity in healthy men. Arterioscler Thromb Vasc Biol 17 11 (1997) 2861-2867
43. Ridker P.M., Cannon C.P., Morrow D., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 1 (Jan 6 2005) 20-28
44. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 8 (Oct 21 2003) 670-682 [Review]
45. Christenson J.T. Preoperative lipid control with simvastatin protects coronary artery by pass grafts from obstructive graft disease. Am J Cardiol 88 8 (2001) 896-899 [A8]
46. Werba J.P., Tremoli E., Massironi P., et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 76 6 (2003) 2132-2140
47. Christenson J.T. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg 15 4 (1999) 394-399 [discussion 399-400]
48. Chello M., Patti G., Candura D., et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 34 3 (Mar 2006) 660-667
49. Marin F., Pascual D.A., Roldan V., et al. Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg 81 1 (Jan 2006) 78-83
50. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
51. St-Pierre A.C., Cantin B., Bergeron J., et al. Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 182 2 (Oct 2005) 315-321